Baculovirus p6.9 Gene Deletion for Virion-Free Biopharmaceutical Production
Solution Overview
Problem
Current baculovirus-insect cell technology faces challenges in producing biopharmaceuticals due to contamination with baculovirus virions, which complicates purification and reduces efficiency, necessitating the development of a method to minimize or eliminate these contaminants.
Innovation Solution
Infecting insect cells with baculoviruses deficient in the p6.9 gene or using an expression control system to inactivate this gene, thereby reducing or eliminating the production of budded and occlusion-derived virions, allowing for the production of biopharmaceuticals without contaminating baculovirus particles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If baculovirus-insect cell technology is used for biopharmaceutical production, then high levels of recombinant protein expression are achieved, but contamination with baculovirus virions occurs complicating purification
Solution Approach 1:
The invention extracts and removes the harmful p6.9 gene from the baculovirus genome, which is essential for virion assembly. By deleting this specific gene, the system eliminates the production of contaminating budded and occlusion-derived virions while preserving the ability to express recombinant proteins at high levels through the baculovirus expression machinery.
Solution Approach 2:
The invention changes the genetic parameter of the baculovirus by creating a deletion mutant lacking the p6.9 gene. This genetic modification fundamentally alters the virus's ability to assemble complete virions, transforming it from a contaminating system into a controlled expression system that produces proteins without infectious particle contamination.
2Productivity
If baculovirus virions are produced during biopharmaceutical manufacturing, then protein expression is maintained, but purification complexity and processing time increase
Solution Approach 1:
By removing the p6.9 gene from the baculovirus system, the invention extracts the specific function of virion assembly while retaining protein expression capability. This separation eliminates the need for complex purification steps designed to remove viral particles, significantly reducing downstream processing time and complexity.
3Stability of the object's composition
If p6.9 gene is present in baculovirus genome, then complete virion assembly occurs, but contaminating budded and occlusion-derived virions are produced
Solution Approach 1:
The invention specifically extracts and removes the p6.9 gene, which is identified as essential for both budded virion and occlusion-derived virion assembly. This targeted removal disrupts the complete virion assembly pathway, preventing the formation of contaminating particles while leaving the protein expression function intact.
Data Source
Figure 1(A)~1(D)(d)
Figure 2A(a)~2B(b)
Figure 3(A)~3
AI summary
The present invention relates to methods for the production of biopharmaceuticals implementing a baculovirus-based system. These methods advantageously allow the production of biopharmaceuticals with a reduced number of or without contaminating baculoviral virions.